LAMTOR3 and breast carcinoma: In the combined breast cancer sample, rs148972953 in LAMTOR3 was found to be strongly associated with negative progesterone receptor status (OR = 4.27 (1.43–12.72); Table 3) and with negative oestrogen receptor status of the tumour (OR = 3.60 (1.15–11.28); Table 3).